Operational Update: Aurora Cannabis Receives Sales License for Vie Facility in Quebec; First Harvest at Aurora Sky

Operational Update: Aurora Cannabis Receives Sales License for Vie Facility in Quebec; First Harvest in Aurora Sky

 Aurora Cannabis Inc. (TSX: ACB) (OTCQB: ACBFF) (Frankfurt: 21P; WKN: A1C4WM) is very happy to supply the following operational update.

On June 29, 2018, eight months after receiving its climbing license, the Aurora Vie manufacturing facility in Pointe-Claire, Quebec, has been granted its Health Canada revenue license. The facility, now in full commercial operation, is on target to produce at a speed of 4,000 kg per year of high-quality cannabis by October 2018. Multiple harvests have been completed to date.

Modifications of the facility required for softgel manufacturing are materially complete. The business’s strategic partner, Capcium, is now installing equipment to commence high-volume creation of cannabis softgels, a premium market segment.

Located at Edmonton International Airport, Aurora Sky, the world’s most technologically advanced cannabis production facility, has been progress on track towards full operation in late summer. The first harvest was completed on June 28, 2018, using another harvest planned over the next two weeks. Upon completion of the second harvest, the Company will request a Health Canada review towards receiving a revenue license for the facility.

Installation of most automation systems, as well as irrigation and climate control is complete, and the facility’s critical systems are being commissioned. The business anticipates planting of bays in the coming months, ensuring ample dried flower and expressed merchandise supply ahead of customer legalization in October, 2018, with the facility ramping up to full capacity of over 8,000 kg every month by the beginning of 2019. Consequently, the business expects a dramatic increase in product availability across all three market segments: Canadian medical; Canadian mature consumer use; and global medical.

With a entire footprint exceeding 800,000 sq. ft., Aurora Sky is expected to generate more than 100,000 kg annually of high-quality cannabis.

Aurora is poised to enter new high value-added, higher margin segments of the medical and consumer markets. CanniMed has received Health Canada approval to commence sales of CanniMed Capsules, a line of vegan capsules, the first of which – CanniMed Capsules 3:3 — will be available in August, 2018. Each capsule contains a balanced dose of THC and CBD. A top CBD capsule is also under development. Capsules as a delivery mechanism are highly valued for their precision dosing.

Moreover, Aurora has received its Health Canada license for the creation of encapsulated oil for its Mountain facility. The business will be producing unique, integral hard shells for the medical markets, as well as for the mature consumer usage market, once legalized.

Construction Well Underway in Aurora Sun

Ground has been broken for construction of the Aurora Sun production facility in Medicine Hat, Alberta, called the”Sunniest City in Canada”. The appreciable experience gained through the construction of Aurora Sky, the acquisition of Larssen Ltd. and the institution of facility design and technology branch Aurora Larssen Projects Inc. (“ALPS”), as well as the business-friendly climate in Medicine Hat are anticipated to expedite completion of the Aurora Sun project.

Aurora Sun, the second of the business’s EU GMP compliant high technology”Sky Class” facilities with precision environmental controls and a high degree of automation, is currently slated to be 50% bigger than Aurora Sky, at 1.2 million sq. ft., and to generate more than 150,000 kg of high-quality cannabis per year.

The integration of CanniMed Therapeutics into Aurora has now been successfully completed, within the targeted 90 day period, combining Aurora’s implementation and agility with CanniMed’s powerful medical brand, assets and exceptionally experienced team of scientists and operational cannabis professionals. The implementation program developed for CanniMed will support the integration of future acquisitions.

The operational teams have fully completed their technical and procedure review, and manufacturing synergies are being realized. The business anticipates that by bringing CanniMed’s farming procedures in line with the Aurora Standard, the manufacturing capacity within the current footprint will increase significantly over the coming quarters. Likewise, the integration team is implementing enhancements to the extraction operations at CanniMed, which, management expects will increase oil production substantially.

The integration process has also enabled the Company to leverage CanniMed’s currently unused licensed space to support the development and delivery of new product forms in addition to the recently announced launch of a Topical cream and the CanniMed Capsules. The integrated science group is continuing to progress on existing CanniMed initiatives, as well is establishing new projects, leveraging CanniMed’s considerable science and research capabilities.

CanniMed is now integrated into Aurora’s global sales and distribution channels. Additional opportunities to increase Aurora’s and CanniMed’s global reach are being pursued, such as through CanniMed’s relationships in South Africa, the Cayman Islands, and Australia. CanniMed continues to ship oils into both of the latter jurisdictions.

Strengthening the business’s medical brand recognition to support further growth in the global medical cannabis markets has been chased through the continuation of various clinical trials. This program is also anticipated to yield marketable IP.

Headquartered in Edmonton, Alberta, with funded capacity in excess of 430,000 kg annually and operations across Canada and in Europe, Aurora is one of the world’s largest cannabis companies. The business is vertically integrated and horizontally diversified across every key segment of the value chain, from facility design and technology, to cannabis breeding and genetics research, cannabis and hemp production, extraction and higher value-add product development, home cultivation and retail and wholesale distribution.

Highly distinguished from its peers, Aurora has established a uniquely innovative, consistent and effective manufacturing approach, based on purpose-built facilities that integrate leading-edge technology across all processes. Intended to be replicable and scalable worldwide, these manufacturing facilities are designed to make cannabis on a massive scale, with higher flower quality, industry-leading yields, and ultra-low per g production expenses. Each of the business’s facilities is constructed to meet European Union (EU) GMP standards, and its first manufacturing facility and its wholly owned European medical cannabis distributor Pedanios have achieved that level of certification.

In addition to its rapid organic growth and strategic M&A, which to date includes nine companies acquired, Aurora is distinguished by its reputation as a partner of choice from the cannabis industry, having invested in and established strategic partnerships with a wide selection of leading innovators, including: The Green Organic Dutchman Holdings Ltd. (TSX: TGOD), Radient Technologies Inc. (TSXV: RTI), Hempco Food and Fiber Inc. (TSXV: HEMP), Cann Group Ltd. (ASX: CAN), Micron Waste Technologies Inc. (CSE: MWM), Choom Holdings Inc. (CSE: CHOO), Namaste Technologies Inc. (TSXV: N), and Alcanna Inc. (TSX: CLIQ).

To find out more about Aurora, please visit our investor site https://investor.auroramj.com.

Read original release

Published at Tue, 03 Jul 2018 16:14:50 +0000

Posted in: News

Comments are closed.